Quick Answer
Stoke Therapeutics, Inc. reported Common Stock Shares Outstanding of 58.92 million shares for the year ending 2025.
- Stoke Therapeutics, Inc. showed an increase of +9.0% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Stoke Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: 32.67 million shares | Q3 2019: 32.72 million shares | Q1 2020: 32.97 million shares | Q2 2020: 33.21 million shares | Q3 2020: 33.36 million shares | Q1 2021: 36.70 million shares | Q2 2021: 36.72 million shares | Q3 2021: 36.78 million shares | Q1 2022: 39.04 million shares | Q2 2022: 39.38 million shares | Q3 2022: 39.43 million shares | Q1 2023: 44.18 million shares | Q2 2023: 44.20 million shares | Q3 2023: 44.29 million shares | Q1 2024: 46.50 million shares | Q2 2024: 52.31 million shares | Q3 2024: 52.94 million shares | Q1 2025: 54.60 million shares | Q2 2025: 54.72 million shares | Q3 2025: 55.12 million shares.
- Over the full 8 years of available data (2018 to 2025), Stoke Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 8,000.2%.
- Historical annual values: Fiscal year 2025: 58.92 million shares | Fiscal year 2024: 54.03 million shares | Fiscal year 2023: 45.92 million shares | Fiscal year 2022: 39.44 million shares | Fiscal year 2021: 36.90 million shares | Fiscal year 2020: 36.58 million shares | Fiscal year 2019: 32.86 million shares | Fiscal year 2018: 727,413 shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: